Clinical-stage biotechnology company Arvinas (NASDAQ:ARVN) appointed Noah Berkowitz, M.D., Ph.D., to the role of chief medical officer and a member of the executive committee reporting to president and CEO John Houston, Ph.D. effective today.
Dr. Berkowitz will lead the ongoing clinical development of Arvinas’ PROTAC protein degrader programs in oncology and neuroscience.
The company also announced that Ron Peck, M.D., who was chief medical officer since joining Arvinas in mid-2019, will be leaving to pursue other opportunities.